ArticlePractical laboratory medicine2025
Flow cytometry-based validation of soluble biomarker detection.
Article in Practical laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Accurate and reliable measurement of soluble markers, such as sCD25, sCD40L, sCD130, and sTREM-1, is crucial for understanding their roles in immune responses and inflammatory conditions. This study presents the validation of a multiplex flow cytometry assay using the BD FACSLyric flow cytometer, designed to simultaneously quantify these four soluble markers in serum samples. Methods: The assay utilizes a bead-based immunoassay kit that is compatible with BD FACSLyric to enable precise detection of low concentrations of these markers. The methodological approach includes detailed sample preparation, bead conjugation, and assay optimization. Data acquisition was performed on the BD FACSLyric, with a minimum of 10 000 events recorded per sample to ensure robust data collection. Results: The validation results demonstrated that the assay achieved low limits of detection (LOD) for sCD25, sCD40L, sCD130, and sTREM-1. The LOD values were respectively 9.77 pg/ml, 43.95 pg/ml, 219.73 pg/ml, and 12.21 pg/ml, indicating the assay's high sensitivity. Reproducibility was confirmed through intra-assay and inter-assay variability assessments. Studies have shown that the levels of sCD25/sCD40L/sTREM-1 in the body are associated with lung cancer. Therefore, this study also used this detection method to test both lung cancer patients and healthy individuals, finding significant differences in the results, which can be used to assist in clinical diagnosis and treatment. Conclusions: This assay's ability to detect multiple analytes in a single run, combined with its high sensitivity and reproducibility, makes it a valuable asset for both research and clinical applications. Future work may expand this assay to include additional markers or adapt it for other sample types, further enhancing its utility in diverse biomedical contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.